BRIEF-Health Canada authorizes ProMetic to proceed with PBI-4050 clinical trial

Wed May 18, 2016 7:13am EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

May 18 (Reuters) - ProMetic Life Sciences Inc Says To Commence Clinical Trial Of Its Orally Active Anti

* Says to commence clinical trial of its orally active anti-fibrotic lead drug candidate, PBI-4050

* Phase 2 clinical trial of PBI-4050 to commence in Q2 2016 as planned

* Health Canada authorizes ProMetic to proceed with its PBI-4050 clinical trial in patients with cystic fibrosis Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)